| Literature DB >> 33228195 |
Aušra Nemeikaitė-Čėnienė1, Jonas Šarlauskas2, Lina Misevičienė2, Audronė Marozienė2, Violeta Jonušienė3, Mindaugas Lesanavičius2, Narimantas Čėnas2.
Abstract
Derivatives of tirapazamine and other heteroaromatic N-oxides (ArN→O) exhibit tumoricidal, antibacterial, and antiprotozoal activities, which are typically attributed to bioreductive activation and free radical generation. In this work, we aimed to clarify the role of NAD(P)H:quinone oxidoreductase (NQO1) in ArN→O aerobic cytotoxicity. We synthesized 9 representatives of ArN→O with uncharacterized redox properties and examined their single-electron reduction by rat NADPH:cytochrome P-450 reductase (P-450R) and Plasmodium falciparum ferredoxin:NADP+ oxidoreductase (PfFNR), and by rat NQO1. NQO1 catalyzed both redox cycling and the formation of stable reduction products of ArN→O. The reactivity of ArN→O in NQO1-catalyzed reactions did not correlate with the geometric average of their activity towards P-450R- and PfFNR, which was taken for the parameter of their redox cycling efficacy. The cytotoxicity of compounds in murine hepatoma MH22a cells was decreased by antioxidants and the inhibitor of NQO1, dicoumarol. The multiparameter regression analysis of the data of this and a previous study (DOI: 10.3390/ijms20184602) shows that the cytotoxicity of ArN→O (n = 18) in MH22a and human colon carcinoma HCT-116 cells increases with the geometric average of their reactivity towards P-450R and PfFNR, and with their reactivity towards NQO1. These data demonstrate that NQO1 is a potentially important target of action of heteroaromatic N-oxides.Entities:
Keywords: NAD(P)H:quinone oxidoreductase; cytotoxicity; oxidative stress; reductive activation; tirapazamine
Mesh:
Substances:
Year: 2020 PMID: 33228195 PMCID: PMC7699506 DOI: 10.3390/ijms21228754
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Pathways of the reduction of tirapazamine in the cell.
Figure 1Formulae of heteroaromatic N-oxides used in this work: derivatives of tirapazamine (1–5), quinoxaline-1,4-dioxide (6,7), and 1,2,4-benzotriazine-1-oxide (8,9).
The single-electron reduction midpoint potentials (E17) of aromatic N-oxides, the steady-state bimolecular rate constants (kcat/Km) of their reduction by P-450R and PfFNR, and the logs of the geometric averages of their reactivity (log kcat/Km (avge)).
| No. | Compound | log | |||
|---|---|---|---|---|---|
| P-450R | |||||
| 1 | 7-CF3O-tirapazamine | 4.6 ± 0.4 × 104 | 3.8 ± 0.4 × 104 | 4.62 | |
| 2 | 3-CH3CONH-1,2,4-benzotriazine-1,4-dioxide | 7.0 ± 0.5 × 104 | 6.2 ± 0.5 × 104 | 4.82 | |
| 3 | 3-CH3OCONH-1,2,4-benzotriazine-1,4-dioxide | 8.0 ± 0.9 × 104 | 4.8 ± 0.4 × 104 | 4.78 | |
| 4 | 3-CF3SO2NH-1,2,4-benzotriazine-1,4-dioxide | 2.5 ± 0.3 × 104 | 2.6 ± 0.3 × 104 | 4.41 | |
| 5 | 3-CH3SO2NH-1,2,4-benzotriazine-1,4-dioxide | 2.7 ± 0.3 × 103 | 7.9 ± 0.5 × 103 | 3.67 | |
| 6 | 2-CF3-quinoxaline-1,4-dioxide | (−0.465) b | 2.7 ± 0.3 × 104 | 8.9 ± 0.7 × 103 | 4.19 |
| 7 | 2-NH2-3-CN-quinoxaline-1,4-dioxide | 4.7 ± 0.4 × 103 | 1.8 ± 0.2 × 104 | 3.96 | |
| 8 | 1,2,4-Benzotriazine-1-oxide | (−0.431) b | 1.7 ± 0.2 × 104 | 4.3 ± 0.3 × 103 | 3.94 |
| 9 | 3-CH3CONH-1,2,4-benzotriazine-1-oxide | 8.7 ± 0.9 × 103 | 1.6 ± 0.1 × 103 | 3.58 | |
| ArN→O with available | |||||
| 10 | 1,2,4-Benzotriazine-1,4-dioxide | −0.318 | 4.3 ± 0.4 × 105 c | 2.5 ± 0.3 × 104 | 5.00 |
| 11 | 7-CF3-tirapazamine | −0.345 | 8.7 ± 0.7 × 104 c | 5.2 ± 0.4 × 104 d | 4.83 |
| 12 | 7-Cl-tirapazamine | −0.400 | 6.9 ± 0.7 × 104 c | 3.7 ± 0.4 × 104 d | 4.71 |
| 13 | 7-F-tirapazamine | −0.400 | 3.4 ± 0.3 × 104 c | 2.7 ± 0.2 × 104 d | 4.48 |
| 14 | Tirapazamine | −0.455 | 1.1 ± 0.1 × 104 c | 4.4 ± 0.5 × 103 d | 3.84 |
| 15 | 7-CH3-tirapazamine | −0.474 | 8.6 ± 0.7 × 103 c | 5.0 ± 0.6 × 103 d | 3.82 |
| 16 | 7-C2H5O-tirapazamine | −0.494 | 4.5 ± 0.5 × 103 c | 4.5 ± 0.5 × 103 d | 3.65 |
| 17 | 3-Amino-1,2,4-benzotriazine-1-oxide | −0.568 | 2.8 ± 0.2 × 103 c | 3.2 ± 0.2 × 103 d | 3.48 |
| 18 | Quinoxaline-1,4-dioxide | −0.575 | 3.3 ± 0.2 × 103 c | 8.2 ± 0.9 × 102 d | 3.22 |
aE17 of compounds taken from Ref. [7,31,32], b Calculated using the E17 differences between compounds 11 and 14, 0.110 V, and compounds 17 and 14, −0.113 V, respectively, c Taken from Ref. [22], d Taken from Ref. [27].
The steady-state rate constants of reduction of aromatic N-oxides by NQO1 and their calculated van der Waals volumes (VdWvol).
| No. | Compound | VdWvol (Å3) a | ||
|---|---|---|---|---|
| 1 | 7-CF3O-tirapazamine | 0.11 ± 0.02 | 1.6 ± 0.1 × 103 | 175.8 |
| 2 | 3-CH3CONH-1,2,4-benzotriazine-1,4-dioxide | 3.40 ± 0.20 | 1.3 ± 0.1 × 104 | 172.3 |
| 3.00 ± 0.20 b | 1.0 ± 0.1 × 104 b | |||
| 3 | 3-CH3OCONH-1,2,4-benzotriazine-1,4-dioxide | 2.40 ± 0.22 | 3.0 ± 0.2 × 103 | 180.7 |
| 4 | 3-CF3SO2NH-1,2,4-benzotriazine-1,4-dioxide | 0.34 ± 0.06 | 1.0 ± 0.2 × 103 | 203.5 |
| 5 | 3-CH3SO2NH-1,2,4-benzotriazine-1,4-dioxide | 0.40 ± 0.05 | 1.2 ± 0.2 × 103 | 184.9 |
| 6 | 2-CF3-quinoxaline-1,4-dioxide | 13.5 ± 1.72 | 2.4 ± 0.2 × 104 | 168.2 |
| 7 | 2-NH2-3-CN-quinoxaline-1,4-dioxide | 0.11 ± 0.02 | 1.4 ± 0.1 × 103 | 146.2 |
| 8 | 1,2,4-Benzotriazine-1-oxide | 1.10 ± 0.12 | 2.1 ± 0.2 × 103 | 111.7 |
| 9 | 3-CH3CONH-1,2,4-benzotriazine-1-oxide | 0.06 ± 0.02 | 5.0 ± 1.0 × 102 | 163.5 |
| 10 | 1,2,4-Benzotriazine-1,4-dioxide c | 1.00 ± 0.10 | 5.1 ± 0.7 × 103 | 120.5 |
| 11 | 7-CF3-tirapazamine c | 1.30 ± 0.10 | 3.7 ± 0.4 × 103 | 167.0 |
| 12 | 7-Cl-tirapazamine c | 1.00 ± 0.10 | 4.3 ± 0.4 × 103 | 152.6 |
| 13 | 7-F-tirapazamine c | 0.70 ± 0.10 | 4.9 ± 0.6 × 103 | 143.5 |
| 14 | Tirapazamine c | 0.20 ± 0.10 | 2.4 ± 0.2 × 103 | 131.5 |
| 15 | 7-CH3-tirapazamine c | 0.30 ± 0.05 | 1.7 ± 0.1 × 103 | 148.8 |
| 16 | 7-C2H5O-tirapazamine c | 0.30 ± 0.04 | 1.0 ± 0.1 × 103 | 174.9 |
| 17 | 3-Amino-1,2,4-benzotriazine-1-oxide c | 0.10 ± 0.02 | 1.6 ± 0.2 × 103 | 122,7 |
| 18 | Quinoxaline-1,4-dioxide c | 0.60 ± 0.10 | 7.9 ± 0.9 × 103 | 126.8 |
a Calculated according to [34], b Determined in the absence of activators, c Taken from Ref. [22].
Figure 2Reduction of 3-CH3CONH-1,2,4-benzotriazine-1,4-dioxide (2) by NAD(P)H:quinone oxidoreductase (NQO1). (A) The spectral changes of 200 µM (2) in the presence of 50 nM NQO1, and 50 µM NADPH and NADPH regeneration system. The absorbance of NADPH is shown by a dashed line. The scans are recorded each 15 min. (B) The rates of NQO1-catalyzed oxidation of NADPH (1,2), reduction of cytochrome c (3–6), and depletion of 200 µM (2) in the presence of 200 µM NADPH (7). Additions: NADPH (1), NADPH + (2) (2,7), NADPH + cytochrome c (3), NADPH + cytochrome c + 100 U/mL SOD (4), NADPH + (2) + cytochrome c (5), NADPH + (2) + cytochrome c + SOD (6), n = 3, p < 0.01 for 3 against 4 and for 5 against 6.
The logarithms of the geometric averages of ArN→O reactivity in P450R- and PfFNR-catalyzed reactions (log kcat/Km (avge)), their octanol/water distribution coefficients at pH 7.0 (log D), their concentrations for 50% cell survival (cL50) in murine hepatoma MH22a cells, and their concentrations causing 50% maximal proliferation inhibition (GI50) of human colon carcinoma HCT-116 cells.
| No. | Compound | log | log | cL50 (µM) MH22a | GI50 (µM) HCT-116 |
|---|---|---|---|---|---|
| 1 | 7-CF3O-tirapazamine | 4.62 | 1.32 | 3.6 ± 0.7 | 17 ± 3.0 |
| 2 | 3-CH3CONH-1,2,4-benzotriazine-1,4-dioxide | 4.82 | −0.82 | 1.5 ± 0.3 | 2.5 ± 0.5 |
| 3 | 3-CH3OCONH-1,2,4-benzotriazine-1,4-dioxide | 4.78 | −0.08 | 9.4 ± 1.4 | 6.3 ± 1.0 |
| 4 | 3-CF3SO2NH-1,2,4-benzotriazine-1,4-dioxide | 4.41 | −0.40 | 44 ± 6.5 | 125 ± 19 |
| 5 | 3-CH3SO2NH-1,2,4-benzotriazine-1,4-dioxide | 3.67 | −2.42 | 184 ± 25 | 185 ± 23 |
| 6 | 2-CF3-quinoxaline-1,4-dioxide | 4.19 | 0.42 | 10 ± 2.0 | 12.5 ± 2.0 |
| 7 | 2-NH2-3-CN-quinoxaline-1,4-dioxide | 3.96 | −0.18 | 358 ± 52 | 125 ± 17 |
| 8 | 1,2,4-Benzotriazine-1-oxide | 3.94 | 0.45 | 168 ± 21 | 225 ± 27 |
| 9 | 3-CH3CONH-1,2,4-benzotriazine-1-oxide | 3.58 | 0.37 | ≥600 | ≥1000 |
| 10 | 1,2,4-Benzotriazine-1,4-dioxide | 5.00 | −0.70 | 11 ± 1.5 a | 18 ± 2.0 |
| 11 | 7-CF3-tirapazamine | 4.83 | 0.76 | 3.4 ± 0.4 a | 6.0 ± 1.0 a |
| 12 | 7-Cl-tirapazamine | 4.71 | 0.49 | 3.1 ± 0.5 a | 13 ± 1.5 a |
| 13 | 7-F-tirapazamine | 4.48 | 0.03 | 7.2 ± 1.0 a | 25 ± 4.0 |
| 14 | Tirapazamine | 3.84 | 0.11 | 31 ± 5.5 a | 75 ± 7.0 a |
| 15 | 7-CH3-tirapazamine | 3.82 | 0.40 | 83 ± 10 a | 50 ± 6.0 a |
| 16 | 7-C2H5O-tirapazamine | 3.65 | 0.08 | 64 ± 10 a | 60 ± 7.0 a |
| 17 | 3-Amino-1,2,4-benzotriazine-1-oxide | 3.48 | 0.30 | ≥600 a | ≥600 a |
| 18 | Quinoxaline-1,4-dioxide | 3.22 | −0.90 | 325 ± 40 a | ≥800 |
a Taken from Ref. [22].
Modulation of the cytotoxicity of aromatic N-oxides in MH22a cells by desferrioxamine (DESF), N,N′-diphenyl-p-phenylenediamine (DPPD), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and dicoumarol (DIC). The additions of compounds did not affect the cell viability in control experiments, 98.5–99.3%, n = 3, * p < 0.05, ** p < 0.02, *** p < 0.01.
| No. | Compound | Cell Viability (%) | ||||
|---|---|---|---|---|---|---|
| No Additions | Additions: | |||||
| DESF (1.0 mM) | DPPD (2.5 µM) | BCNU (20 µM) | DIC (20 µM) | |||
| 1 | 3-CH3CONH-1,2,4-benzotriazine-1,4-dioxide, 1.5 µM | 47.2 ± 4.0 | 71.8 ± 4.0 *** | 64.9 ± 3.8 *** | 34.0 ± 3.0 ** | 83.7 ± 6.1 *** |
| 2 | 2-NH2-3-CN-quinoxaline-1,4-dioxide, 350 µM | 47.3 ± 4.2 | 83.5 ± 7.0 ** | 72.1 ± 5.7 ** | 35.3 ± 3.6 * | 71.6 ± 5.1 ** |
| 3 | 1,2,4-Benzotriazine-1,4-dioxide, 10 µM | 55.6 ± 4.5 | n.d. | n.d. | n.d. | 81.2 ± 7.4 ** |
| 4 | 3-CF3SO2NH-1,2,4-benzotriazine-1,4-dioxide, 40 µM | 55.8 ± 4.9 | n.d. | n.d. | n.d. | 79.0 ± 3.1 ** |
| 5 | 2-CF3-quinoxaline-1,4-dioxide, 10 µM | 57.6 ± 4.5 | n.d. | n.d. | n.d. | 83.1 ± 5.6 ** |
The results of the multiparameter analysis of ArN→O cytotoxicity (Table 3) according to Equation (3).
| Cell Line |
|
|
|
|
|
|---|---|---|---|---|---|
| 7.22 ± 0.80 | −1.36 ± 0.19 | - | - | 0.7638 | |
| MH22a | 7.07 ± 0.84 | −1.33 ± 0.20 | −0.09 ± 0.13 | - | 0.7704 |
| 8.44 ± 0.88 | −1.20 ± 0.18 | - | −0.55 ± 0.24 | 0.8266 | |
| 8.30 ± 0.88 | −1.14 ± 0.19 | −0.13 ± 0.118 | −0.59 ± 0.24 | 0.8405 | |
| 6.68 ± 0.73 | −1.19 ± 0.17 | - | - | 0.7440 | |
| HCT-116 | 6.63 ± 0.79 | −1.18 ± 0.19 | −0.03 ± 0.13 | - | 0.7448 |
| 7.74 ± 0.82 | −1.05 ± 0.17 | - | −0.48 ± 0.22 | 0.8052 | |
| 7.67 ± 0.85 | −1.02 ± 0.18 | −0.06 ± 0.11 | −0.50 ± 0.23 | 0.8093 |